Beneficial metabolic activities of inflammatory cytokine interleukin 15 in obesity and type 2 diabetes

Jianping Ye

Front. Med. ›› 2015, Vol. 9 ›› Issue (2) : 139 -145.

PDF (306KB)
Front. Med. ›› 2015, Vol. 9 ›› Issue (2) : 139 -145. DOI: 10.1007/s11684-015-0377-z
REVIEW
REVIEW

Beneficial metabolic activities of inflammatory cytokine interleukin 15 in obesity and type 2 diabetes

Author information +
History +
PDF (306KB)

Abstract

In obesity, chronic inflammation is believed to induce insulin resistance and impairs adipose tissue function. Although this view is supported by a large body of literature, it has been challenged by growing evidence that pro-inflammatory cytokines may favor insulin sensitivity through induction of energy expenditure. In this review article, interleukin 15 (IL-15) is used as a new example to explain the beneficial effects of the pro-inflammatory cytokines. IL-15 is secreted by multiple types of cells including macrophages, neutrophils and skeletal muscle cells. IL-15 expression is induced in immune cells by endotoxin and in muscle cells by physical exercise. Its transcription is induced by transcription factor NF-κB. IL-15 binds to its receptor that contains three different subunits (α, β and γ) to activate JAK/STAT, PI3K/Akt, IKK/NF-κB and JNK/AP1 pathways in cells. In the regulation of metabolism, IL-15 reduces weight gain without inhibiting food intake in rodents. IL-15 suppresses lipogenesis, stimulates brown fat function, improves insulin sensitivity through weight loss and energy expenditure. In human, circulating IL-15 is negatively associated with body weight. In the immune system, IL-15 stimulates proliferation and differentiation of T cells, NK cells, monocytes and neutrophils. In the anti-obesity effects of IL-15, T cells and NK cells are not required, but leptin receptor is required. In summary, evidence from human and rodents supports that the pro-inflammatory cytokine IL-15 may enhance energy expenditure to protect the body from obesity and type 2 diabetes. The mechanism of IL-15 action remains to be fully uncovered in the regulation of energy expenditure.

Keywords

inflammation / obesity / cytokine / energy expenditure / insulin resistance

Cite this article

Download citation ▾
Jianping Ye. Beneficial metabolic activities of inflammatory cytokine interleukin 15 in obesity and type 2 diabetes. Front. Med., 2015, 9(2): 139-145 DOI:10.1007/s11684-015-0377-z

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Hotamisligil GS. Inflammation and metabolic disorders. Nature2006; 444(7121): 860–867

[2]

Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev2007; 21(12): 1443–1455

[3]

Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol2010; 72(1): 219–246

[4]

Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol2011; 11(2): 98–107

[5]

Saltiel AR. Insulin resistance in the defense against obesity. Cell Metab2012; 15(6): 798–804

[6]

De Souza CT, Araujo EP, Bordin S, Ashimine R, Zollner RL, Boschero AC, Saad MJ, Velloso LA. Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus. Endocrinology2005; 146(10): 4192–4199

[7]

Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKKβ/NF-kB and ER stress link overnutrition to energy imbalance and obesity. Cell2008; 135(1): 61–73

[8]

Kleinridders A, Schenten D, Könner AC, Belgardt BF, Mauer J, Okamura T, Wunderlich FT, Medzhitov R, Brüning JC. MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab2009; 10(4): 249–259

[9]

Holland WL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, Knotts TA, Shui G, Clegg DJ, Wenk MR, Pagliassotti MJ, Scherer PE, Summers SA. Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice. J Clin Invest2011; 121(5): 1858–1870

[10]

Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Görgün C, Glimcher LH, Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science2004; 306(5695): 457–461

[11]

Lee YS, Kim JW, Osborne O, Oh Y, Sasik R, Schenk S, Chen A, Chung H, Murphy A, Watkins SM, Quehenberger O, Johnson RS, Olefsky JM. Increased adipocyte O2 consumption triggers HIF-1α, causing inflammation and insulin resistance in obesity. Cell2014; 157(6): 1339–1352

[12]

Qiu Y, Nguyen KD, Odegaard JI, Cui X, Tian X, Locksley RM, Palmiter RD, Chawla A. Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. Cell2014; 157(6): 1292–1308

[13]

Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, Jedrychowski MP, Ruas JL, Wrann CD, Lo JC, Camera DM, Lachey J, Gygi S, Seehra J, Hawley JA, Spiegelman BM. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell2014; 157(6): 1279–1291

[14]

Ye J, McGuinness OP. Inflammation during obesity is not all bad: evidence from animal and human studies. Am J Physiol Endocrinol Metab2013; 304(5): E466–E477

[15]

Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell2012; 148(5): 852–871

[16]

Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell2013; 152(4): 673–684

[17]

Pedersen BK, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol2012; 8(8): 457–465

[18]

Ye J. Mechanisms of insulin resistance in obesity. Front Med2013; 7(1): 14–24

[19]

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta2011; 1813(5): 878–888

[20]

Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood2001; 97(1): 14–32

[21]

Azimi N, Brown K, Bamford RN, Tagaya Y, Siebenlist U, Waldmann TA. Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kB site. Proc Natl Acad Sci USA1998; 95(5): 2452–2457

[22]

Washizu J, Nishimura H, Nakamura N, Nimura Y, Yoshikai Y. The NF-kB binding site is essential for transcriptional activation of the IL-15 gene. Immunogenetics1998; 48(1): 1–7

[23]

Tamura Y, Watanabe K, Kantani T, Hayashi J, Ishida N, Kaneki M. Upregulation of circulating IL-15 by treadmill running in healthy individuals: is IL-15 an endocrine mediator of the beneficial effects of endurance exercise? Endocr J2011; 58(3): 211–215

[24]

Quinn LS, Anderson BG, Conner JD, Wolden-Hanson T. IL-15 overexpression promotes endurance, oxidative energy metabolism, and muscle PPARδ, SIRT1, PGC-1α, and PGC-1β expression in male mice. Endocrinology2013; 154(1): 232–245

[25]

Vijayakumar A, Wu Y, Sun H, Li X, Jeddy Z, Liu C, Schwartz GJ, Yakar S, LeRoith D. Targeted loss of GHR signaling in mouse skeletal muscle protects against high-fat diet-induced metabolic deterioration. Diabetes2012; 61(1): 94–103

[26]

Hiromatsu T, Yajima T, Matsuguchi T, Nishimura H, Wajjwalku W, Arai T, Nimura Y, Yoshikai Y. Overexpression of interleukin-15 protects against Escherichia coli-induced shock accompanied by inhibition of tumor necrosis factor-α-induced apoptosis. J Infect Dis2003; 187(9): 1442–1451

[27]

Orinska Z, Maurer M, Mirghomizadeh F, Bulanova E, Metz M, Nashkevich N, Schiemann F, Schulmistrat J, Budagian V, Giron-Michel J, Brandt E, Paus R, Bulfone-Paus S. IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. Nat Med2007; 13(8): 927–934

[28]

Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev2006; 17(4): 259–280

[29]

Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K, DuBose R, Cosman D, Park LS, Anderson DM. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J 1995; 14(15): 3654–3663

[30]

Quinn LS, Anderson BG. Interleukin-15, IL-15 receptor-α, and obesity: concordance of laboratory animal and human genetic studies. J Obesity2011; 2011: 456347

[31]

Vallabhapurapu S, Powolny-Budnicka I, Riemann M, Schmid RM, Paxian S, Pfeffer K, Körner H, Weih F. Rel/NF-κB family member RelA regulates NK1.1- to NK1.1+ transition as well as IL-15-induced expansion of NKT cells. Eur J Immunol2008; 38(12): 3508–3519

[32]

McDonald PP, Russo MP, Ferrini S, Cassatella MA. Interleukin-15 (IL-15) induces NF-kB activation and IL-8 production in human neutrophils. Blood1998; 92(12): 4828–4835

[33]

Chenoweth MJ, Mian MF, Barra NG, Alain T, Sonenberg N, Bramson J, Lichty BD, Richards CD, Ma A, Ashkar AA. IL-15 can signal via IL-15Rα, JNK, and NF-κB to drive RANTES production by myeloid cells. J Immunol2012; 188(9): 4149–4157

[34]

Stone KP, Kastin AJ, Pan W. NFkB is an unexpected major mediator of interleukin-15 signaling in cerebral endothelia. Cell Physiol Biochem2011; 28(1): 115–124

[35]

Giron-Michel J, Caignard A, Fogli M, Brouty-Boyé D, Briard D, van Dijk M, Meazza R, Ferrini S, Lebousse-Kerdilès C, Clay D, Bompais H, Chouaib S, Péault B, Azzarone B. Differential STAT3, STAT5, and NF-kB activation in human hematopoietic progenitors by endogenous interleukin-15: implications in the expression of functional molecules. Blood2003; 102(1): 109–117

[36]

Nielsen AR, Hojman P, Erikstrup C, Fischer CP, Plomgaard P, Mounier R, Mortensen OH, Broholm C, Taudorf S, Krogh-Madsen R, Lindegaard B, Petersen AM, Gehl J, Pedersen BK. Association between interleukin-15 and obesity: interleukin-15 as a potential regulator of fat mass. J Clin Endocrinol Metab2008; 93(11): 4486–4493

[37]

Carbó N, López-Soriano J, Costelli P, Alvarez B, Busquets S, Baccino FM, Quinn LS, López-Soriano FJ, Argilés JM. Interleukin-15 mediates reciprocal regulation of adipose and muscle mass: a potential role in body weight control. Biochim Biophys Acta2001; 1526(1): 17–24

[38]

Quinn LS, Anderson BG, Strait-Bodey L, Stroud AM, Argilés JM. Oversecretion of interleukin-15 from skeletal muscle reduces adiposity. Am J Physiol Endocrinol Metab2009; 296(1): E191–E202

[39]

Barra NG, Reid S, MacKenzie R, Werstuck G, Trigatti BL, Richards C, Holloway AC, Ashkar AA. Interleukin-15 contributes to the regulation of murine adipose tissue and human adipocytes. Obesity (Silver Spring)2010; 18(8): 1601–1607

[40]

Alvarez B, Carbó N, López-Soriano J, Drivdahl RH, Busquets S, López-Soriano FJ, Argilés JM, Quinn LS. Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochim Biophys Acta2002; 1570(1): 33–37

[41]

Almendro V, Fuster G, Busquets S, Ametller E, Figueras M, Argilés JM, López-Soriano FJ. Effects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARs. Obesity (Silver Spring)2008; 16(2): 285–289

[42]

Almendro V, Busquets S, Ametller E, Carbó N, Figueras M, Fuster G, Argilés JM, López-Soriano FJ. Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)C]-triolein load. Biochim Biophys Acta2006; 1761(1): 37–42

[43]

López-Soriano J, Carbó N, Almendro V, Figueras M, Ribas V, Busquets S, López-Soriano FJ, Argilés JM. Rat liver lipogenesis is modulated by interleukin-15. Int J Mol Med 2004; 13(6): 817–819

[44]

Barra NG, Chew MV, Holloway AC, Ashkar AA. Interleukin-15 treatment improves glucose homeostasis and insulin sensitivity in obese mice. Diabetes Obes Metab2012; 14(2): 190–193

[45]

Barra NG, Chew MV, Reid S, Ashkar AA. Interleukin-15 treatment induces weight loss independent of lymphocytes. PLoS ONE2012; 7(6): e39553

RIGHTS & PERMISSIONS

Higher Education Press and Springer-Verlag Berlin Heidelberg

AI Summary AI Mindmap
PDF (306KB)

2815

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/